Shanghai Haohai Biological Technology Co (688366.SS) Stock Price

Shanghai Haohai Biological Technology Co Price

🇨🇳SSE·CLOSED
31.60CNY
Market closed
Today +/-
Today %

Shanghai Haohai Biological Technology Co (688366.SS) Stock | ISIN CNE100003NX4. The current Shanghai Haohai Biological Technology Co stock price is 31.6 CNY (2026). Revenue is 2.91 B CNY. Net income is 568.8 M CNY. The P/E ratio is 12.98. Market capitalization is 7.38 B CNY. Shanghai Haohai Biological Technology Co operates in the Health sector.

Shanghai Haohai Biological Technology Co stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Shanghai Haohai Biological Technology Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Shanghai Haohai Biological Technology Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Shanghai Haohai Biological Technology Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Shanghai Haohai Biological Technology Co Stock Price History
DateShanghai Haohai Biological Technology Co Price
Access this data via the Eulerpool API

Shanghai Haohai Biological Technology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2016
861.2 M CNY
279.8 M CNY
305.1 M CNY
Jan 1, 2017
1.35 B CNY
403.5 M CNY
372.4 M CNY
Jan 1, 2018
1.56 B CNY
441.8 M CNY
414.5 M CNY
Jan 1, 2019
1.6 B CNY
350.4 M CNY
370.8 M CNY
Jan 1, 2020
1.33 B CNY
122.4 M CNY
230.1 M CNY
Jan 1, 2021
1.77 B CNY
234.05 M CNY
352.24 M CNY
Jan 1, 2022
2.13 B CNY
206.29 M CNY
180.47 M CNY
Jan 1, 2023
2.65 B CNY
438.53 M CNY
416.12 M CNY
Jan 1, 2024
2.7 B CNY
416.44 M CNY
420.45 M CNY
Invalid Date
2.66 B CNY
441.58 M CNY
470.18 M CNY
Invalid Date
2.91 B CNY
536.94 M CNY
568.8 M CNY
Invalid Date
3.19 B CNY
649.7 M CNY
685.34 M CNY

Shanghai Haohai Biological Technology Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 12:38 PM
 
REVENUE (M CNY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M CNY)
NET INCOME (M CNY)
NET INCOME GROWTH (%)
DIV. (CNY)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Shanghai Haohai Biological Technology Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Shanghai Haohai Biological Technology Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Shanghai Haohai Biological Technology Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Shanghai Haohai Biological Technology Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Shanghai Haohai Biological Technology Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Shanghai Haohai Biological Technology Co stock margins

The Shanghai Haohai Biological Technology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Haohai Biological Technology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Haohai Biological Technology Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2016
83.57 %
32.49 %
35.43 %
Jan 1, 2017
78.63 %
29.79 %
27.5 %
Jan 1, 2018
78.51 %
28.35 %
26.6 %
Jan 1, 2019
77.28 %
21.84 %
23.11 %
Jan 1, 2020
74.64 %
9.19 %
17.27 %
Jan 1, 2021
72.14 %
13.25 %
19.93 %
Jan 1, 2022
68.6 %
9.68 %
8.47 %
Jan 1, 2023
70.25 %
16.52 %
15.68 %
Jan 1, 2024
68.68 %
15.44 %
15.59 %
Invalid Date
68.68 %
16.58 %
17.65 %
Invalid Date
68.68 %
18.46 %
19.56 %
Invalid Date
68.68 %
20.38 %
21.5 %

Shanghai Haohai Biological Technology Co Stock Revenue, EBIT, Earnings per Share

The Shanghai Haohai Biological Technology Co earnings per share therefore indicates how much revenue Shanghai Haohai Biological Technology Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2016
5.38 CNY
1.75 CNY
1.91 CNY
Jan 1, 2017
8.47 CNY
2.52 CNY
2.33 CNY
Jan 1, 2018
9.74 CNY
2.76 CNY
2.59 CNY
Jan 1, 2019
9.82 CNY
2.15 CNY
2.27 CNY
Jan 1, 2020
7.53 CNY
0.69 CNY
1.3 CNY
Jan 1, 2021
7.18 CNY
0.95 CNY
1.43 CNY
Jan 1, 2022
8.77 CNY
0.85 CNY
0.74 CNY
Jan 1, 2023
11.12 CNY
1.84 CNY
1.74 CNY
Jan 1, 2024
11.55 CNY
1.78 CNY
1.8 CNY
Invalid Date
11.41 CNY
1.89 CNY
2.01 CNY
Invalid Date
12.45 CNY
2.3 CNY
2.44 CNY
Invalid Date
13.65 CNY
2.78 CNY
2.93 CNY

Shanghai Haohai Biological Technology Co business model & stock analysis

Shanghai Haohai Biological Technology Co Ltd was founded in 2004 and has since become a significant company in the pharmaceutical and biotechnology industry. The company is headquartered in Shanghai, China and operates multiple production facilities in the region. The business model of Shanghai Haohai Biological Technology Co Ltd is to manufacture and sell high-quality pharmaceutical and biotechnology products. The company focuses on research and development to find innovative solutions for various applications. The company's divisions are diverse and range from the development and production of interferon and insulin to the production of vaccines and blood products. The products of Shanghai Haohai Biological Technology Co Ltd are used worldwide in medicine, pharmacy, and biotechnology. One of the company's most important products is interferon, which is used for protection against viral infections. In addition, the company also produces insulin, which is used in the treatment of diabetes mellitus. The insulin of Shanghai Haohai Biological Technology Co Ltd is of high quality and is highly regarded by medical professionals worldwide. Another important division of the company is the production of vaccines. In recent years, the company has developed innovative vaccines against various diseases such as influenza, HPV, and hepatitis B. These vaccines are of high quality and are distributed worldwide. Shanghai Haohai Biological Technology Co Ltd also has a wide range of blood products that are used in medicine and transfusion medicine. The blood products are manufactured under strict quality controls to ensure maximum safety. The company distributes its products in China and globally and is a key player in the global market. The history of Shanghai Haohai Biological Technology Co Ltd is characterized by success and innovation. The company was founded in 2004 and has become a leading company in the pharmaceutical and biotechnology industry in a short period of time. In recent years, the company has focused on the development and production of high-quality products and expansion into new markets. It has always adhered to its corporate values of quality, innovation, and sustainability. Overall, Shanghai Haohai Biological Technology Co Ltd is an innovative and successful company that is among the leading players in the pharmaceutical and biotechnology industry. With its wide range of products, research and development work, and high quality standards, the company has made a name for itself and is an important partner for medical professionals and patients worldwide.

Shanghai Haohai Biological Technology Co SWOT Analysis

Strengths

Shanghai Haohai Biological Technology Co Ltd possesses several strengths that contribute to its competitive advantage in the market. These strengths include:

  • Strong Research and Development capabilities
  • Advanced technology infrastructure
  • Extensive product portfolio
  • Strong brand reputation
  • Well-established distribution network

Weaknesses

Despite its strengths, Shanghai Haohai Biological Technology Co Ltd also faces certain weaknesses that can hinder its growth and performance. These weaknesses include:

  • Limited global market presence
  • Dependence on a few key suppliers
  • Relative lack of brand awareness in international markets
  • Higher production costs compared to some competitors

Opportunities

Shanghai Haohai Biological Technology Co Ltd can leverage various opportunities to expand its market presence and enhance its business prospects. These opportunities include:

  • Growing demand for bio-based products
  • Expansion into emerging markets
  • Collaboration with research institutions and academia
  • Product diversification into new sectors

Threats

Shanghai Haohai Biological Technology Co Ltd must also be mindful of potential threats that could impact its business operations and performance. These threats include:

  • Intense competition from domestic and international firms
  • Changing regulatory environment and compliance requirements
  • Fluctuating raw material prices
  • Economic uncertainties and market fluctuations

Shanghai Haohai Biological Technology Co Eulerpool Fair Value

Shanghai Haohai Biological Technology Co historical P/E ratio, EBIT multiple, and P/S ratio

Shanghai Haohai Biological Technology Co annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Shanghai Haohai Biological Technology Co shares outstanding

The number of shares was Shanghai Haohai Biological Technology Co in 2025 — This indicates how many shares 233.582 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2016
160 M base_Shares
Jan 1, 2017
160 M base_Shares
Jan 1, 2018
160 M base_Shares
Jan 1, 2019
163.3 M base_Shares
Jan 1, 2020
177 M base_Shares
Jan 1, 2021
246.15 M base_Shares
Jan 1, 2022
242.94 M base_Shares
Jan 1, 2023
238.76 M base_Shares
Jan 1, 2024
233.58 M base_Shares
Invalid Date
233.58 M base_Shares
Invalid Date
233.58 M base_Shares
Invalid Date
233.58 M base_Shares

Shanghai Haohai Biological Technology Co Dividend History

6 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251CNY 10.3%
Jun 30, 20250.6CNY 50.0%1/2
Oct 16, 20250.4CNY 33.3%2/2
20241.11CNY 178.6%
20230.4CNY 42.9%
20220.7CNY 40.0%
20210.5CNY 28.6%
20200.7CNY

Shanghai Haohai Biological Technology Co dividend history and estimates

In 2025, Shanghai Haohai Biological Technology Co paid a dividend amounting to 1 CNY. Dividend means that Shanghai Haohai Biological Technology Co distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
0.7 CNY
0 CNY
Jan 1, 2021
0.5 CNY
0 CNY
Jan 1, 2022
0.7 CNY
0 CNY
Jan 1, 2023
0.4 CNY
0 CNY
Jan 1, 2024
1.11 CNY
0 CNY
Jan 1, 2025
1 CNY
0 CNY
Invalid Date
0 CNY
1.14 CNY
Invalid Date
0 CNY
1.41 CNY

Shanghai Haohai Biological Technology Co dividend payout ratio

In 2025, Shanghai Haohai Biological Technology Co had a payout ratio of 52.05%. The payout ratio indicates the percentage of the company's profits that Shanghai Haohai Biological Technology Co distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2016
43.57 %
Jan 1, 2017
43.57 %
Jan 1, 2018
43.57 %
Jan 1, 2019
43.57 %
Jan 1, 2020
38.46 %
Jan 1, 2021
24.95 %
Jan 1, 2022
67.3 %
Jan 1, 2023
43.57 %
Jan 1, 2024
45.28 %
Invalid Date
52.05 %
Invalid Date
46.97 %
Invalid Date
48.1 %
Price targets and forecasts for Shanghai Haohai Biological Technology Co are not yet available.

Shanghai Haohai Biological Technology Co shareholder structure

% Name
28.4817%
Jiang (Wei)
Jiang (Wei)
17.26163%
You (Jie)
You (Jie)
3.63715%
Wu (Jianying)
Wu (Jianying)
3.59993%
Hou (Yongtai)
Hou (Yongtai)
3.04828%
Lou (Guo Liang)
Lou (Guo Liang)
1.6962%
Peng (Jin Hua)
Peng (Jin Hua)
1.19872%
Huang (Ming)
Huang (Ming)
1.19872%
Liu (Yuan Zhong)
Liu (Yuan Zhong)
0.32942%
China Southern Asset Management Co. Ltd.
China Southern Asset Management Co. Ltd.
0.23637%
Bosera Asset Management Co., Ltd.
Bosera Asset Management Co., Ltd.
...

Shanghai Haohai Biological Technology Co Executives and Management Board

JW

Mr. Jianying Wu

(55)

General Manager, Executive Director · since 2010

Compensation1.47 M CNY
YH

Mr. Yongtai Hou

(63)

Executive Chairman of the Board · since 2010

Compensation1.34 M CNY
MT

Mr. Minjie Tang

(50)

Finance Director, Executive Director · since 2016

Compensation1.22 M CNY
YC

Ms. Yiyi Chen

(38)

Executive Director · since 2014

Compensation1.09 M CNY
JZ

Mr. Jundong Zhang

(51)

Deputy General Manager

Compensation934,600 CNY

Shanghai Haohai Biological Technology Co Supply Chain

Frequently asked questions about Shanghai Haohai Biological Technology Co

The business model of Shanghai Haohai Biological Technology Co Ltd focuses on the development, production, and sale of pharmaceutical products. As a leading biotechnology company in China, Shanghai Haohai Biological Technology Co Ltd primarily engages in the research and manufacturing of innovative medicines, including both chemical drugs and biological drugs. By leveraging its extensive expertise in the biopharmaceutical industry, the company aims to provide effective and safe healthcare solutions to patients worldwide. With a strong emphasis on technological innovation and quality control, Shanghai Haohai Biological Technology Co Ltd strives to become a trusted provider of advanced pharmaceutical products, contributing to the improvement of global healthcare standards.